rss
Br J Ophthalmol doi:10.1136/bjo.2009.158931

Intravitreal Bevacizumab Therapy for Neovascular Age Related Macular Degeneration Associated with Poor Initial Visual Acuity

  1. Tural Galbinur (tural001{at}yahoo.com),
  2. Edward Averbukh (edwaver{at}gmail.com),
  3. Eyal Banin (banine{at}cc.huji.ac.il),
  4. Itzhak Hemo (hemoy{at}cc.huji.ac.il),
  5. Itay Chowers (chowers{at}hadassah.org.il)
  1. Hadassah Medical Center, Israel
  2. Hadassah Medical Center, Israel
  3. Hadassah Medical Center, Israel
  4. Hadassah Medical Center, Israel
  5. Hadassah Medical Center, Israel
    • Published Online First 10 June 2009

    Abstract

    Aim: To assess the efficacy of intravitreal bevacizumab injections for eyes with neovascular age related macular degeneration (NVAMD) and poor initial visual acuity (VA).

    Methods: Retrospective study of 44 consecutive treatment-naïve eyes with NVAMD who had initial VA of 0.1 decimal or worse, and that were treated with intravitreal bevacizumab injections. For the purpose of the study, charts, optical coherence tomography (OCT), and fluorescein angiograms (FA) were reviewed.

    Results: Mean lesion size (SD) was 3375±2116 micron, all lesions showed sub- or intra-retinal fluid in OCT, and active neovascularization composed 41.6±17.7% (range 10-90%) of the lesion area according to FA. Patients received a mean of 2.6±2.42 bevacizumab injections (range: 1-14), and mean VA improved from 1.85±0.64 LogMAR to 1.52±0.77 LogMAR (p = 0.002). At final exam, 9 eyes (20%) had reduced VA, 10 eyes (23%) had stable VA, and 25 eyes (57%) had improved VA compared with baseline, respectively. Following treatment, mean macular thickness reduced from 332±98 micron to 248±79 micron (p < 0.0001).

    Conclusions: Poor initial VA should not refrain from using bevacizumab in eyes with NVAMD. Selection of patients with signs of active neovascularization based on ophthalmoscopy, OCT, and FA may increase the likelihood of favorable response to treatment.

    This Article

    1. Abstract
    2. PDF
    3. All versions of this article:
      1. bjo.2009.158931v1
      2. 93/10/1351most recent

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.